Sebi Imposes One-Year Ban on Two Individuals for Insider Trading in Jagsonpal Pharmaceuticals

The Securities and Exchange Board of India (Sebi) has taken action against two individuals for insider trading in Jagsonpal Pharmaceuticals' shares. They are barred from the securities markets for a year and face a combined fine of Rs 25 lakh. Specifically, Maneesh Kumar Jain was fined Rs 15 lakh, while S V Subha Rao, the former CFO of Jagsonpal Pharmaceuticals Ltd, received a Rs 10 lakh penalty.

Representative image

In addition to the fines, Sebi has ordered Maneesh Kumar Jain to return Rs 31.39 lakh with 12% annual interest from February 22, 2022, until the deposit date. Sebi's order highlighted that Rao shared unpublished price-sensitive information (UPSI) about a significant share acquisition with Jain. This led to Jain trading Jagsonpal Pharmaceuticals Ltd (JPL) shares on February 21, 2022, during the UPSI period, breaching PIT rules.

Insider Trading Investigation

Sebi found that Jain traded JPL shares using UPSI from Rao about a major share acquisition, resulting in an unlawful gain of Rs 31.39 lakh. Consequently, Sebi stated that Jain violated Prohibition of Insider Trading (PIT) regulations. The order followed a detailed analysis by NSE to identify clients whose trading patterns indicated potential UPSI-based trading.

The investigation period spanned from December 2021 to March 2022. Sebi conducted an in-depth investigation to determine if the suspected entity traded JPL shares while possessing UPSI and if any Sebi norms were breached. Based on trading pattern analysis, Sebi identified Maneesh Kumar Jain as a suspect.

Communication Between Suspects

Sebi's examination of call data records revealed that Maneesh Kumar Jain frequently communicated with then-JPL CFO S V Subha Rao during the relevant period. This frequent contact raised suspicions about insider trading activities involving JPL shares.

This case underscores the importance of adhering to insider trading regulations and maintaining market integrity. Sebi's actions aim to deter similar violations and uphold fair trading practices in the securities markets.